In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aldeyra Therapeutics, Inc.

http://www.aldeyra.com/

Latest From Aldeyra Therapeutics, Inc.

Aldeyra Thinks It May Have Broadly Applicable Retinitis Pigmentosa Therapy

Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.

Clinical Trials Drug Approval Standards

Aldeyra All Set For Double Date With The FDA

The US agency is reviewing two of the US biotech’s drug with decisions expected on its methotrexate product for ocular lymphoma by June and on the dry eye drug reproxalap in November, as Aldeyra mulls its marketing strategy for both.

Ophthalmic Drug Review

Keeping Track: Opdivo, Keytruda Continue Adjuvant Push As Cancer Dominates Recent Applications

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Cancer US FDA Performance Tracker

Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

United States US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Aldexa Therapeutics, Inc.
    • Helio Vision, Inc.
    • Neuron Systems, Inc.
UsernamePublicRestriction

Register